Literature DB >> 19155405

Contrast-enhanced sonography of nonfunctioning pancreatic neuroendocrine tumors.

Roberto Malagò1, Mirko D'Onofrio, Giulia A Zamboni, Niccolò Faccioli, Massimo Falconi, Letizia Boninsegna, Roberto Pozzi Mucelli.   

Abstract

OBJECTIVE: Diagnosis of malignancy and prognostic assessment continue to be problems in the management of nonfunctioning pancreatic endocrine tumors. Histologic examination is the reference standard. The aim of our study was to compare B-mode and contrast-enhanced sonographic findings regarding nonfunctioning pancreatic endocrine tumors. Signs of malignancy, such as Ki67 index and presence of hepatic metastasis, were considered.
MATERIALS AND METHODS: We retrospectively reviewed the cases of 38 consecutively registered patients with nonfunctioning pancreatic endocrine tumors evaluated with B-mode and contrast-enhanced sonography and resected. At contrast-enhanced sonography all lesions were divided into hypovascular lesions and isovascular or hypervascular lesions. On the basis of homogeneity of enhancement, lesions were classified as homogeneous and inhomogeneous. During the late phase of contrast enhancement, all solid focal hypoechoic liver lesions detected at contrast-enhanced sonography were considered hepatic metastatic lesions. Among pathologic data, grading, mitotic index, and Ki67 index were evaluated. Spearman's test was used to compare contrast-enhanced sonographic enhancement pattern with pathologic grade.
RESULTS: In the arterial phase, 24 of 38 nonfunctioning pancreatic endocrine tumors (63.1%) were hypervascular, seven (18.4%) were isovascular, and seven (18.4%) were hypovascular. Positive correlation was found between contrast-enhanced sonographic findings and Ki67 index (r(s) = 0.62; p < 0.0001). The difference between contrast-enhanced and B-mode sonography in the diagnosis of nonfunctioning pancreatic endocrine tumors was statistically significant (p < 0.05). Use of contrast-enhanced sonography increased diagnostic confidence in the detection of hepatic metastasis. The areas under the receiver operating characteristic curves were 0.916 for B-mode sonography and 1.000 for contrast-enhanced sonography (p < 0.05). There was moderate positive correlation between contrast-enhanced sonographic enhancement pattern and the presence of hepatic metastasis at diagnosis (r(s) = 0.46; p = 0.004) and between Ki67 index and the presence of hepatic metastasis (r(s) = 0.48; p = 0.0022).
CONCLUSION: The contrast-enhanced sonographic enhancement pattern of nonfunctioning pancreatic endocrine tumors has a positive correlation with Ki67 index, which is considered the most reliable independent predictor of the presence of malignancy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19155405     DOI: 10.2214/AJR.07.4043

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  15 in total

1.  Contrast enhanced ultrasound with quantitative perfusion analysis for objective characterization of pancreatic ductal adenocarcinoma: A feasibility study.

Authors:  Mirko D'Onofrio; Stefano Canestrini; Stefano Crosara; Riccardo De Robertis; Roberto Pozzi Mucelli
Journal:  World J Radiol       Date:  2014-03-28

2.  Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors.

Authors:  M Del Prete; A Di Sarno; R Modica; F Lassandro; A Giorgio; A Bianco; M Muto; M Gasperi; F Del Prete; A Colao; V Montesarchio; A Faggiano
Journal:  J Endocrinol Invest       Date:  2017-06-30       Impact factor: 4.256

3.  Preoperative assessment of nonfunctioning pancreatic endocrine tumours: role of MDCT and MRI.

Authors:  Giovanni Foti; Letizia Boninsegna; Massimo Falconi; Roberto Pozzi Mucelli
Journal:  Radiol Med       Date:  2013-07-25       Impact factor: 3.469

4.  Pancreatic Neuroendocrine Tumor presenting as a diffuse pancreatic enlargement, case report and review of literature.

Authors:  Faeze Salahshour; Reza Taslimi; Najme-Sadat Moosavi; Niloofar Ayoobi Yazdi; Mohsen Esfandbod
Journal:  J Radiol Case Rep       Date:  2021-01-31

Review 5.  Pancreatic neuroendocrine tumors.

Authors:  Shailesh V Shrikhande; Bhawna Sirohi; Mahesh Goel; Savio G Barreto
Journal:  Indian J Gastroenterol       Date:  2012-10-03

Review 6.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

Review 7.  [Modern sonographic imaging of abdominal neuroendocrine tumors].

Authors:  V Schwarze; C Marschner; S Grosu; J Rübenthaler; T Knösel; D-A Clevert
Journal:  Radiologe       Date:  2019-11       Impact factor: 0.635

Review 8.  Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities.

Authors:  Ali Pirasteh; Petra Lovrec; Lisa Bodei
Journal:  Rev Endocr Metab Disord       Date:  2021-03-30       Impact factor: 9.306

9.  Clinical controversies in endoscopic ultrasound.

Authors:  Arvind J Trindade; Tyler M Berzin
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-04-19

Review 10.  Contrast-enhanced endoscopic ultrasound.

Authors:  Christoph F Dietrich; M Sharma; M Hocke
Journal:  Endosc Ultrasound       Date:  2012-10       Impact factor: 5.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.